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Abstract
Objective
To determine the eﬀect of erenumab, a human monoclonal antibody targeting the calcitonin
gene-related peptide receptor, on health-related quality of life (HRQoL), headache impact, and
disability in patients with chronic migraine (CM).
Methods
In this double-blind, placebo-controlled study, 667 adults with CMwere randomized (3:2:2) to
placebo or erenumab (70 or 140 mg monthly). Exploratory endpoints included migraine-
speciﬁc HRQoL (Migraine-Speciﬁc Quality-of-Life Questionnaire [MSQ]), headache impact
(Headache Impact Test–6 [HIT-6]), migraine-related disability (Migraine Disability Assess-
ment [MIDAS] test), and pain interference (Patient-Reported Outcomes Measurement In-
formation System [PROMIS] Pain Interference Scale short form 6b).
Results
Improvements were observed for all endpoints in both erenumab groups at month 3, with
greater changes relative to placebo observed at month 1 for many outcomes. All 3 MSQ
domains were improved from baseline with treatment diﬀerences for both doses exceeding
minimally important diﬀerences established for MSQ–role function-restrictive (≥3.2) and
MSQ–emotional functioning (≥7.5) and for MSQ–role function-preventive (≥4.5) for ere-
numab 140 mg. Changes from baseline in HIT-6 scores at month 3 were −5.6 for both doses vs
−3.1 for placebo. MIDAS scores at month 3 improved by −19.4 days for 70 mg and −19.8 days
for 140 mg vs −7.5 days for placebo. Individual-level minimally important diﬀerence was
achieved by larger proportions of erenumab-treated participants than placebo for all MSQ
domains andHIT-6. Lower proportions of erenumab-treated participants hadMIDAS scores of
severe (≥21) or very severe (≥41) or PROMIS scores ≥60 at month 3.
Conclusions
Erenumab-treated patients with CM experienced clinically relevant improvements across
a broad range of patient-reported outcomes.
Clinicaltrials.gov identifier
NCT02066415.
Classification of evidence
This study provides Class II evidence that for patients with CM, erenumab treatment improves
HRQoL, headache impact, and disability.
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Migraine is a disabling neurologic disorder aﬀecting 15% of the
global population.1–5 Disability increases progressively with in-
creasing frequency of migraine headache days; patients with
chronic migraine (CM), who comprise approximately 10% of the
total migraine population, are most disabled.4,6 Migraine and its
associated symptoms result in decreased health-related quality of
life (HRQoL), social and psychological impact, and increased
disability.2,4,5,7 In addition to reducing the frequency, intensity,
and duration of attacks, international treatment guidelines state
that preventive treatments for migraine should restore ability to
function.8 Erenumab (in the United States, erenumab-aooe) is
a fully human anti-canonical calcitonin gene-related peptide
(CGRP) receptor monoclonal antibody approved in the United
States for migraine prevention,9 with demonstrated clinically
relevant eﬃcacy in CM.10 The clinical safety and eﬃcacy of
erenumab was assessed in a pivotal, randomized, double-blind,
placebo-controlled study of patients with CM. Erenumab 70 and
140 mg showed signiﬁcant reductions from baseline in monthly
migraine days compared with placebo (both doses 6.6 days vs
placebo 4.2 days) with a safety proﬁle similar to placebo.10
Herein, we present a secondary analysis of these clinical trial data
to examine the eﬀect of erenumab treatment onmultiple patient-
reported outcomes (PROs) measuring a broad range of com-
plementary outcomes in patients with CM following 3months of
treatment.
Methods
The objective of this analysis was to assess the eﬃcacy of
erenumab on HRQoL, headache impact, and disability in
patients with CM. This study provides Class II evidence that
for patients with CM, erenumab treatment improves HRQoL,
headache impact, and disability.
Patients and data source
This was an exploratory analysis of PRO data from a pivotal
study that evaluated safety and eﬃcacy of erenumab in
patients with CM (≥15 headache days per month, of which ≥8
were migraine days). The eligibility criteria, design, and pri-
mary results of the phase 2 study were previously published.10
The study comprised 667 participants at 69 study sites
worldwide. Participants were randomized to 1 of 3 treatment
arms in a 3:2:2 ratio (placebo, erenumab 70, or erenumab
140 mg monthly) stratiﬁed by region (North America vs
other) and medication overuse (yes or no) for a 3-month
double-blind treatment phase.
Standard protocol approvals, registrations,
and patient consents
The study was approved by an independent ethics committee
or local institutional review board at each participating site.
Written informed consent was obtained from all enrolled
participants. The study was conducted in accordance with the
International Conference on Harmonisation Tripartite
Guideline on Good Clinical Practice. Clinicaltrials.gov iden-
tiﬁer: NCT02066415.
Outcome measures
Migraine-Specific Quality-of-Life Questionnaire
The Migraine-Speciﬁc Quality-of-Life Questionnaire (MSQ)
is a self-administered, migraine-speciﬁc, 14-item instrument
assessment of quality of life that was developed to assess the
eﬀect of migraine on daily functioning across 3 domains.11,12
The role function-restrictive (MSQ-RFR) domain measures
the eﬀect of migraine on daily social and work-related activ-
ities, the role function-preventive (MSQ-RFP) domain
assesses whether migraine prevents the individual from per-
forming these activities, and the emotional functioning
(MSQ-EF) domain measures emotions associated with mi-
graine. Items are rated on a 6-point scale (none of the time,
a little bit of the time, some of the time, a good bit of the time,
most of the time, and all of the time). Raw domain scores are
summed and transformed to a 100-point scale with higher
scores indicating better quality of life and increased scores
consistent with improvement. The between-group minimally
important diﬀerence (MID) for MSQ-RFR is 3.2, for MSQ-
RFP is 4.6, and for MSQ-EF is 7.5.13 For within-group anal-
yses for each participant’s change with responder analyses, the
MID is 5.0 for MSQ-RFR, 5.0–7.9 for MSQ-RFP, and
8.0–10.6 for MSQ-EF.13 In the clinical trial, the MSQ was
completed at baseline and then every 4 weeks during the study
using an eDiary.
Headache Impact Test–6
The Headache Impact Test–6 (HIT-6) is a short-form, self-
administered questionnaire developed as a global measure of
adverse headache impact to assess headache severity using
widely measured, functionally relevant domains: pain, social
and role limitations, cognitive functioning, vitality, and psy-
chological distress.14,15 The 6 questions are scored 6, 8, 10, 11,
or 13 points based on 5 response categories that assess how
often headaches interfere with activities or cause distress
(never, rarely, sometimes, very often, or always). Scores for all
Glossary
CGRP = calcitonin gene-related peptide; CI = conﬁdence interval; CM = chronic migraine; EF = emotional functioning;HIT-
6 = Headache Impact Test–6; HRQoL = health-related quality of life; MID = minimally important diﬀerence; MIDAS =
Migraine Disability Assessment; MMD = monthly migraine days; MSQ = Migraine-Speciﬁc Quality-of-Life Questionnaire;
PREEMPT = Phase 3 Research Evaluating Migraine Prophylaxis Therapy; PRO = patient-reported outcome; PROMIS =
Patient-Reported Outcomes Measurement Information System; RFP = role function-preventive; RFR = role function-
restrictive.
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6 items are summed to produce a total HIT-6 score (range:
36–78), interpreted as little or no impact (49 or less), some
impact (50–55), substantial impact (56–59), and severe impact
(60–78) due to headache with higher scores indicating greater
impact and decreased scores consistent with improvement.
The between-group MID for HIT-6 in CM is 2.3 points16 and
the within-patient MID for HIT-6 is a score reduction of 5.0
points.17 The recall period for 3 questions is 1 month and the
other 3 do not have a speciﬁc recall period. The HIT-6 was
completed every 4 weeks during the study using an eDiary.
Migraine Disability Assessment test
The Migraine Disability Assessment (MIDAS) test is a 5-item
self-administered questionnaire that sums the number of pro-
ductive days lost over the past 3 months in the workplace and
assesses disability in family, social, and leisure activities at home
(e.g., Howmany days in the last 3months was the patient at least
50% disabled at work, home, school, or recreational activities due
tomigraine?).18 In addition to a total score, there are subdomains
of absenteeism (missed days, attributable to a headache, from
paidwork, housework, and nonwork activities) and presenteeism
(days at paid work or housework in which productivity was
reduced by at least half).MIDAS scores are interpreted as grade I
= 0–5 (minimal or infrequent disability), grade II = 6–10 (mild
or infrequent disability), grade III = 11–20 (moderate disability),
grade IVa = 21–40 and higher (severe disability), grade IVb = 41
and higher (very severe disability) with higher scores indicating
greater disability and decreased scores consistent with im-
provement. Although no MID has been established for MIDAS,
a preliminary analysis based on an anchor of 25% change in
monthly headache days estimated that an increase or decrease of
5 days of migraine-related disability per 3 months represents
meaningful within-patient change.19 MIDAS was completed at
the end of the 3-month treatment period using an eDiary.
Pain Interference Scale short form 6b
The Patient-Reported Outcomes Measurement Information
System (PROMIS) Pain Interference Scale short form 6b is
a 6-item instrument that measures the level of pain in-
terference on enjoyment of life, ability to concentrate, day-
to-day activities, enjoyment of recreational activities, doing
activities away from home, and socializing with others.20
Each question is scored on a 5-point scale, summed, and
translated into a t score or standardized score with a mean of
50 (average for the US general population) and an SD of 10.
The transformed PROMIS Pain Interference 6b short form t
scores range from 41 to 78.3 with higher scores indicating
greater interference and decreased scores consistent with
improvement. No MID has been established for the
PROMIS Pain Interference Scale for patients with migraine.
The recall period used was the past 7 days, and participants
completed the PROMIS Pain Interference Scale short form
weekly during the study using the eDiary.
Statistical analysis
Descriptive analyses were conducted reporting the change
from baseline and proportion of patients achieving clinically
relevant changes from baseline. Descriptive comparisons be-
tween erenumab groups and placebo are reported as diﬀer-
ences in change from baseline or odds ratios, respectively.
Changes from baseline in PRO scores were preplanned ex-
ploratory endpoints. Dichotomized endpoints were post hoc
exploratory endpoints. Diﬀerences in MSQ, HIT-6, and
PROMIS scores were assessed based on a generalized linear
mixed model including treatment, visit, treatment by visit
interaction, stratiﬁcation factors (region and medication
overuse), and baseline value as covariates and assuming a ﬁrst-
order autoregressive covariance structure. There was no im-
putation for missing data. Diﬀerences in MIDAS scores were
assessed based on an analysis of covariance model including
treatment, stratiﬁcation factors (region and medication
overuse), and baseline value as covariates. MSQ subdomains
and HIT-6 were dichotomized based on respective MIDs
(MSQ-RFR ≥5, MSQ-RFP ≥5, MSQ-EF ≥8, HIT-6 ≥5),
PROMIS was dichotomized based on 1 SD worse than the
average US general population (≥60), and MIDAS was di-
chotomized based on severe (≥21) and very severe (≥41)
ratings. The randomization analysis set included all partic-
ipants who were randomized in the study. The eﬃcacy anal-
ysis set included participants who received ≥1 dose of
randomized treatment and completed at least one postbase-
line monthly eDiary measurement. No formal hypothesis was
tested. The p values for the diﬀerence between erenumab dose
groups and placebo were not adjusted for multiple
comparisons.
Data availability
Qualiﬁed researchers may request data from Amgen clinical
studies. Complete details are available at amgen.com/
datasharing.
Results
Participants and baseline
Of 667 participants randomized, 83% were female with
a mean (SD) age of 42 (11) years (table 1). Mean duration
since ﬁrst migraine diagnosis was 22 (12) years and partic-
ipants had a mean 18.0 (4.6) monthly migraine days and 20.8
(3.9) monthly headache days during the baseline period
(table 1). Baseline PRO scores, which were similar among
treatment groups, were reﬂective of the severe eﬀect of mi-
graine (table 1).
Changes in PRO score over time
MSQ scores
MSQ scores at baseline were similar among treatment groups
and were indicative of substantial limitations to daily social
and work-related activities with scores of approximately 45,
60, and 53 for MSQ-RFR, MSQ-RFP, and MSQ-EF, re-
spectively (table 1). At month 3, increases from baseline
(improvements) in all 3 MSQ domain scores were greater in
the erenumab groups compared with placebo (ﬁgure 1). The
least-squares mean (95% conﬁdence interval [CI]) changes
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from baseline in MSQ-RFR were 17.7 (14.9, 20.6) for 70 mg
and 19.1 (16.3, 22.0) for 140 mg vs 11.8 (9.4, 14.1) for pla-
cebo. Respective changes for MSQ-RFP were 13.0 (10.5,
15.6) and 13.8 (11.3, 16.4) vs 8.9 (6.8, 11.0) and for MSQ-EF
were 18.2 (15.0, 21.3) and 18.8 (15.6, 21.9) vs 9.9 (7.3, 12.5).
These diﬀerences from placebo were observed at the earliest
time point assessed, month 1, and were observed throughout
the double-blind period (ﬁgure 1). At month 3, the diﬀerences
between the erenumab groups and placebo exceeded the
established group-level MID for all MSQ domains for both
doses except for MSQ-RFP with the erenumab 70-mg group
(ﬁgure 1). At month 3, a greater proportion of participants in
the erenumab group than in the placebo group had changes in
MSQ scores that exceeded the within-patient MID for all 3
subdomains (table 2). There were moderately negative linear
relationships between change in MSQ scores and change in
monthly migraine days (MMD) (correlation coeﬃcient r
values ranged from −0.61 to −0.45 in the active treatment
groups) that were signiﬁcantly diﬀerent from zero (p < 0.001)
(ﬁgures 4, A–C).
HIT-6 scores
Mean total HIT-6 score at baseline, similar among treatment
groups, was approximately 63 (table 1), reﬂective of severe
Table 1 Demographics and baseline disease characteristics
Placebo (n = 286)
Erenumab
70 mg (n = 191) 140 mg (n = 190)
Age, y 42.1 (11.3) 41.4 (11.3) 42.9 (11.1)
Sex, female, n (%) 226 (79) 166 (87) 160 (84)
Race, white, n (%) 268 (94) 176 (92) 184 (97)
History of prophylactic failure, n (%) 200 (70) 127 (67) 126 (66)
Faileda ≥2 medications 142 (50) 93 (49) 92 (48)
Ever used topiramate (yes), n (%) 150 (52) 89 (47) 97 (51)
Ever used onabotulinumtoxinA (yes), n (%) 65 (23) 50 (26) 43 (23)
Baseline period
Monthly migraine days 18.2 (4.7) 17.9 (4.4) 17.8 (4.7)
Monthly headache days 21.1 (3.9) 20.5 (3.8) 20.7 (3.8)
Monthly migraine attacks 4.2 (1.7) 4.5 (1.7) 4.3 (1.6)
Monthly acute migraine-specific medication use, d 9.5 (7.6) 8.8 (7.2) 9.7 (7.0)
Acute migraine-specific medication use, n (%) 225 (79) 143 (75) 149 (78)
Baseline patient-reported outcome scoresb n = 281 n = 188 n = 187
MSQ, range 0–100
Role function-restrictive 42.8 (17.6) 44.7 (18.3) 45.6 (19.1)
Role function-preventive 60.3 (20.0) 61.9 (21.6) 62.9 (21.1)
Emotional functioning 53.0 (25.8) 53.6 (25.3) 56.7 (26.6)
HIT-6 total score, range 36–78 63.3 (5.2) 63.4 (5.0) 62.7 (5.6)
MIDAS (last 3 mo before study)
Total score 68.0 (56.0) 65.8 (45.8) 60.9 (52.2)
Presenteeism 33.3 (28.4) 30.3 (24.4) 28.4 (25.9)
Absenteeism 34.7 (33.9) 35.5 (32.2) 32.5 (35.7)
PROMIS Interference, range 41–78.3 63.9 (4.1) 63.2 (4.5) 63.4 (4.8)
Abbreviations: HIT-6 = Headache Impact Test–6; MIDAS = Migraine Disability Assessment; MSQ = Migraine-Specific Quality-of-Life Questionnaire; PROMIS =
Patient-Reported Outcomes Measurement Information System.
Data represent mean (SD) unless otherwise indicated. Randomization analysis set used for analysis.
a Failure attributable to lack of efficacy or adverse events.
b Efficacy analysis set used for analysis.
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impact of headaches (>60). Atmonth 3,mean (SE)HIT-6 scores
were 57.6 (0.5) for 70mg and 57.0 (0.6) for 140mg vs 60.2 (0.4)
for placebo and reﬂected greater changes from baseline. The
change from baseline in total HIT-6 score was greater in the
erenumab groups than in placebo as early as month 1 and was
sustained throughout the double-blind period (ﬁgure 2). The
least-squares mean (95% CI) changes from baseline at month 3
in HIT-6 were −5.6 (−6.5, −4.6) for both 70 mg and 140 mg vs
−3.1 (−3.9, −2.3) for placebo. The between-group HIT-6 MID
(≥1.5 points) was achieved at months 2 and 3 for both doses and
by month 1 for 140 mg erenumab. A greater proportion of
erenumab-treated participants than placebo achieved the within-
patient MID for HIT-6 (score reduction of ≥5 points) at month
3, indicating improvement (table 2). There was a moderately
positively linear relationship between change in HIT-6 score and
change in MMD (correlation coeﬃcient r values ranged from
0.53 to 0.62 in the active treatment groups) that were signiﬁcantly
away from zero (p < 0.001) (ﬁgure 4D).
MIDAS scores
MIDAS scores at baseline indicated severe disability; at
baseline, 81.9% of participants had MIDAS scores of ≥21
(severe disability) and 61.4% had scores of ≥41 (very severe
disability). Reductions from baseline to month 3 in MIDAS
total, absenteeism, and presenteeism scores were greater in
the erenumab groups as compared with placebo, indicating
better improvement (ﬁgure 3). The least-squares mean (95%
CI) changes from baseline in MIDAS total scores were −19.4
(−25.2, −13.6) for 70mg and −19.8 (−25.6, −14.0) for 140mg
vs −7.5 (−12.4, −2.7) for placebo. Respective changes for
absenteeism were −10.3 (−13.6, −6.9) and −10.2 (−13.6,
−6.8) vs −5.2 (−8.0, −2.4) and for presenteeism were −9.3
(−12.6, −6.1) and −9.9 (−13.2, −6.7) vs −1.9 (−4.7, 0.8). At
month 3, a lower proportion of participants in the erenumab
groups had MIDAS scores ≥21 compared with placebo (table
2). Likewise, the proportion of participants with MIDAS
scores ≥41 was lower in the erenumab groups than in the
placebo group (table 2). There was a moderately positive
linear relationship between change in MIDAS score and
change in total migraine days over the 12-week double-blind
treatment phase (correlation coeﬃcient r values ranged from
0.34 to 0.44 in the active treatment groups) that were sig-
niﬁcantly away from zero (p < 0.001) (ﬁgure 4E).
PROMIS scores
PROMIS scores at baseline (mean 63.4) suggested participants
had pain interference >1 SDworse than the average US general
population. At month 3, decreases in PROMIS scores were
greater (better) in the erenumab groups as compared with
placebo (ﬁgure 5). The least-squares mean (95% CI) changes
from baseline in PROMIS scores were −6.5 (−7.4, −5.6) for
70mg and−7.1 (−8.0, −6.2) for 140mg vs −4.5 (−5.2, −3.8) for
placebo. The response to erenumab 140-mg dosage was ob-
served as early as month 1. At month 3, 50.0% of participants in
the placebo group, compared with 32.5% and 34.2% of ere-
numab 70 and 140 mg, had PROMIS scores ≥60 (table 2).
Discussion
CM is a severely disabling disease associated with poor
HRQoL as a result of headache, associated symptoms, and
comorbidities.1,4,6 Currently, there are few evidenced-based
treatment options that patients can use to manage CM.
Figure 1 Change in Migraine-Specific Quality-of-Life Questionnaire (MSQ) scores from baseline over 3 months
Least-squares (LS) mean changes from baseline in (A) MSQ–role function-restrictive (MSQ-RFR), (B) MSQ–role function-preventive (MSQ-RFP), and (C)
MSQ–emotional functioning (MSQ-EF) scores among participantswith chronicmigrainewhowere assigned to receive erenumab70mg, erenumab 140mg, or
placebo everymonth. The error bars represent 95% confidence intervals (CIs). Figure based on the efficacy analysis set. All p values ≤0.05, except forMSQ-RFP
at month 2: erenumab 70 mg, p = 0.051, and erenumab 140 mg, p = 0.061. MID = minimally important difference.
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Erenumab is eﬀective in reducing monthly migraine days in
patients with CM.10 Both erenumab 70 and 140 mg reduced
monthly migraine days by 6.6 days compared with 4.2 days for
placebo (mean treatment diﬀerence −2.5).10 PROs are designed
to capture the eﬀect ofmigraine beyond simple counts ofmigraine
days and can be used to more completely represent the patient
perspective and experience. PROs provide context to more fully
characterize the eﬀect of illness and the beneﬁts of treatment.
HIT-6 and MIDAS, the most frequently used PRO instru-
ments in headache studies, measure headache impact and
migraine-speciﬁc disability. HIT-6 assesses headache severity
by determining how often headaches interfere with activities
or cause distress, whereas MIDAS measures the number of
productive days lost, and the MSQ assesses the eﬀect of mi-
graine on daily functioning. The mean total HIT-6 score of
approximately 63 is reﬂective of the severe impact of head-
aches (>60), consistent with the 61% of patients with MIDAS
scores ≥41 (very severe disability). Likewise, the baseline
MSQ scores were reﬂective of substantial impairments in
migraine-speciﬁc quality of life. In contrast to the headache-
speciﬁc measures, PROMIS is a more generic instrument,
Table 2 Patient-reported outcome responder rates at month 3
Placebo (n = 281)
Erenumab
70 mg (n = 188) 140 mg (n = 187)
MSQ
MSQ-RFR (≥5 increase from baseline) 162 (61.6) 125 (69.4) 131 (73.6)
Adjusted odds ratio (95% CI)a 1.9 (1.1, 3.3) 2.8 (1.6, 4.9)
p Valueb 0.031 <0.001
MSQ-RFP (≥5 increase from baseline) 162 (61.6) 120 (66.7) 121 (68.0)
Adjusted odds ratio (95% CI)a 1.5 (0.9, 2.6) 1.6 (0.9, 2.8)
p Valueb 0.13 0.085
MSQ-EF (≥8 increase from baseline) 122 (46.4) 108 (60.0) 102 (57.3)
Adjusted odds ratio (95% CI)a 2.4 (1.4, 4.3) 2.4 (1.4, 4.3)
p Valueb 0.003 0.003
HIT-6 total score (≥5 decrease from baseline) 80 (30.5) 89 (49.4) 84 (47.2)
Adjusted odds ratio (95% CI)a 2.3 (1.5, 3.4) 2.3 (1.5, 3.4)
p Valueb <0.001 <0.001
MIDAS (severe or very severe disability)
≥21 (severe) 202 (77.7) 112 (62.9) 98 (55.7)
Adjusted odds ratio (95% CI)c 0.4 (0.3, 0.7) 0.4 (0.2, 0.6)
p Valueb <0.001 <0.001
≥41 (very severe) 143 (55.0) 72 (40.4) 65 (36.9)
Adjusted odds ratio (95% CI)c 0.5 (0.3, 0.8) 0.5 (0.3, 0.7)
p Valueb 0.002 <0.001
PROMIS (≥60) 121 (50.0) 53 (32.5) 54 (34.2)
Adjusted odds ratio (95% CI)a 0.3 (0.2, 0.7) 0.3 (0.1, 0.6)
p Valueb 0.003 <0.001
Abbreviations: CI = confidence interval; EF = emotional functioning; HIT-6 = Headache Impact Test–6; MIDAS = Migraine Disability Assessment; MSQ =
Migraine-Specific Quality-of-Life Questionnaire; PROMIS = Patient-Reported Outcomes Measurement Information System; RFP = role function-preventive;
RFR = role function-restrictive.
Data represent n (%). Efficacy analysis set used for analysis.
a Adjusted odds ratios and p values are obtained from a generalized linear mixed model with logit link. Model includes treatment, visit, treatment by visit,
stratification factors region and medication overuse, and baseline value as covariates and assumes a first-order autoregressive covariance structure.
b The p values for pairwise comparisons are nominal p values without multiplicity adjustment.
c Adjusted odds ratios and p values are obtained from a logistic regression model that includes treatment, stratification factors region and medication
overuse, and baseline value as covariates.
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which measures pain interference and allows for comparison
with other disease states and the general population. PROMIS
scores at baseline (mean 63.4) suggested that participants had
pain interference >1 SD worse than the average US general
population. Although each of the PRO measures diﬀerent
aspects of patient well-being, the convergence of the results
indicated how severely CM aﬀected these patients and similar
to ﬁndings of prior CM studies.16,21
The PRO results from this pivotal study showed consistent
beneﬁts of erenumab with improvement across a broad set of
PROs measuring a range of complementary outcomes. The
observed treatment eﬀect on these outcomes exceeded the
established clinically meaningful between-group minimum
diﬀerence for all measures with established MIDs. Moreover,
with one exception (i.e., MSQ-RFP), signiﬁcantly larger
percentages of participants achieved clinically meaningful
Figure 2 Change in Headache Impact Test–6 (HIT-6) total score from baseline over 3 months
Least-squares (LS)mean changes frombaseline inHIT-6
scores among participants with chronic migraine who
were assigned to receive erenumab 70 mg, erenumab
140 mg, or placebo every month. The error bars rep-
resent 95% confidence intervals (CIs). Figure based on
the efficacy analysis set. All p values ≤0.05. MID = min-
imally important difference.
Figure 3 Change in Migraine Disability Assessment (MIDAS) scores from baseline to month 3
Least-squares (LS) mean changes from baseline in (A) MIDAS total, (B) absenteeism, and (C) presenteeism scores among participants with chronic migraine
who were assigned to receive erenumab 70 mg, erenumab 140mg, or placebo every month. The error bars represent 95% confidence intervals (CIs). Figure
based on the efficacy analysis set. All p values ≤0.05.
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improvements in all measures.16 Compared with patients who
reported no change, patients who reported feeling “somewhat
better” had HIT-6 scores diﬀering by 2.3 points, which was
considered evidence of clinically meaningful improvement.16
This thresholdwas achieved atmonths 2 and 3 for both doses and
by month 1 for 140 mg erenumab. Similarly, diﬀerences from
baseline in MIDAS total score were >5 days, indicative of a clin-
ically meaningful change.19 These treatment beneﬁts emerged
early, detected at the ﬁrst 1-month posttreatment assessment (the
earliest time point measured). Treatment beneﬁts were sustained
through the 3-month double-blind phase.
Although improvements in PRO scores correlated with re-
duction in migraine frequency with erenumab treatment, the
proportion of patients achieving an MID with the PROs in
this analysis was higher than the proportion of patients
achieving a ≥50% reduction in MMD. The 50% threshold
(e.g., for reduction in migraine or headache days) is an arbi-
trary way to dichotomize clinical response/nonresponse, and
although widely used in practice and as a clinical trial end-
point, it has been shown that response at a 30% threshold can
be clinically meaningful for patients with CM.22 Achievement
of a 50% response has no direct relationship to the MIDs of
Figure 4 Scatterplots of correlation between change in migraine days and change in patient-reported outcome scores
(A) Migraine-Specific Quality-of-Life Questionnaire–role function-restrictive (MSQ-RFR), (B) Migraine-Specific Quality-of-Life Questionnaire–role function-
preventive (MSQ-RFP), (C) Migraine-Specific Quality-of-Life Questionnaire–emotional functioning (MSQ-EF), (D) Headache Impact Test–6 (HIT-6), and (E)
Migraine Disability Assessment (MIDAS).
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PROs, which are established to identify a clinically meaningful
change on speciﬁc attributes of migraine. This is illustrated by
the onabotulinum toxin A data in the PREEMPT (Phase 3
Research Evaluating Migraine Prophylaxis Therapy) studies
in which only 27% of treated patients had both a ≥5-point
reduction in HIT-6 score and a ≥50% reduction in headache
days. Furthermore, the diﬀerent PROs have entirely diﬀerent
scales, measure diﬀerent domains relevant to patients with
migraine, and the MIDs are speciﬁc to a given PRO;
i.e., clinical relevance for the domain(s) tested is independent
of other PROs, such that for an individual patient it is not
surprising that the relative change on one PRO might be
diﬀerent than the change on a second or third PRO, which
measure diﬀerent facets of relevance to patients. In addition,
the within-patient diﬀerences for the PROs were estimated
based on a variety of methods (e.g., anchor and distribution-
based analyses). Therefore, one would not expect a direct
relationship between MMD ≥50% responder rates and PRO
MIDs. In a preliminary assessment of the relationship be-
tween change in PRO score and change in MMD, we found
that there was a moderate correlation between change in
MMD for each PRO with correlation coeﬃcient r values of
approximately +0.5 or −0.5 for all the PROs. However,
between-subject variation is also observed based on the
scatterplots. Any comparison of PRO “response”with percent
migraine reduction in an individual patient will depend on
what is most meaningful to a patient. Thus, the quantitative
relationship between the level of change in migraine fre-
quency and the level of change in PROs requires a more
detailed and nuanced analysis. Overall, these data demon-
strate that erenumab yields reductions in migraine frequency
that are accompanied by improvements in ability to perform
daily activities and reductions in feelings of hopelessness and/
or frustration from the eﬀect of CM. Further studies are re-
quired to determine the relationship between the level of
change in migraine frequency and the level of change in the
PROs to conﬁrm whether the improvement in PROs is me-
diated by a reduction in headache days.
Clinical trials of parenteral pain treatments consistently report
high placebo rates. Similar to the high placebo response seen
for the primary and secondary endpoints in the main study, the
placebo response rates for the PRO endpoints in this analysis
were high. However, even with these large placebo responses,
the between-group diﬀerences were still clinically relevant.
In previous studies of prevention treatments for CM, top-
iramate consistently showed signiﬁcant reductions in MMD,
but the eﬀect on HRQoL has been mixed. In one study,
MIDAS scores did not signiﬁcantly improve. MSQ scores
were initially improved, but the beneﬁt diminished over
time.23 A separate study of topiramate found no between-
group diﬀerences for MSQ or HIT-6.24 The PREEMPT and
PREEMPT 2 studies showed that onabotulinumtoxinA re-
duced headache days at week 24 by 8.4 days andmigraine days
by 8.2 days compared to 6.6 and 6.2 days, respectively, in the
placebo group.25 These changes in headache frequency were
paralleled by clinically meaningful treatment diﬀerences in
total HIT-6 scores (approximately −2.5) and all 3 MSQ
domains (MSQ-RFR: 17.0 vs 8.6; MSQ-RFP: 13.1 vs 6.4;
MSQ-EF: 17.9 vs 9.5).25,26 Results from these diﬀerent
studies reveal that improvements in clinical outcomes (e.g.,
reductions in MMD) are not necessarily linked to improve-
ments in patient functioning or HRQoL. Some medications
may reduce MMD but produce side eﬀects that oﬀset the
beneﬁts measured by PROs.
Figure 5 Change in Patient-Reported Outcomes Measurement Information System (PROMIS) scores from baseline over 3
months
Least-squares (LS) mean changes from baseline in
PROMIS scores among participants with chronic
migraine who were assigned to receive erenumab
70mg, erenumab 140mg, or placebo everymonth.
The error bars represent 95% confidence intervals
(CIs). Figure based on the efficacy analysis set. All p
values ≤0.01, except for erenumab 70mg at month
1, p = 0.082.
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This large placebo-controlled study demonstrated consis-
tent treatment eﬀects across multiple measures. These
eﬀects may be accounted for by the combination of eﬃcacy
and tolerability erenumab delivers. However, the results may
be limited by the short duration of the study relative to the
time that patients will remain on treatment in the real world.
Further trials are needed to determine the long-term safety
of erenumab and the durability of its eﬀects. Heightened
expectations arising from the promise of CGRP targeted
therapies and the increased clinical attention in the trial,
could lead to overestimation of treatment eﬀects in com-
parison with real-world treatment. These results are unlikely
to diﬀerentially inﬂuence response to active drug and pla-
cebo, however.
Overall, these results demonstrate that erenumab led to sus-
tained, signiﬁcant improvements that are consistent across
multiple measures of HRQoL, social and psychological eﬀect,
and disability in patients with CM. A comparison of this
number of PRO instruments has not been done in such detail
in other migraine preventive trials.
This study provides Class II evidence that erenumab improves
HRQoL, headache impact, and disability in patients with CM.
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